Monday, May 21, 2018
 
 
Company News: Page (1) of 1 - 04/23/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Anpac Bio Wins 2018 International 'BIG Innovation Award'
 
(April 23, 2018)

SACRAMENTO, Calif., April 23, 2018 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced today that Anpac Bio has won the highly-prestigious, international, "2018 BIG Innovation Award".

Anpac Bio-Medical Science Company was named 2018 "BIG Innovation Award" Winner, in recognition of its global, "game-changing" research and services - particularly related to its breakthrough, “Cancer Differentiation Analysis” (CDA) liquid biopsy technology. The only company worldwide, fully-commercialized and earning revenue providing liquid biopsy screening, Anpac Bio's proprietary (200+ patents filed to date) CDA identifies 26+ different, early-stage cancers from a single, low-cost blood test.

Recognizing the corporation for executing significant and consistent innovation through its worldwide research and services, Anpac Bio was particularly acknowledged as an international, "Big Innovation Award" winner, due to its breakthrough and rapidly expanding, "Cancer Differentiation Analysis" (CDA) liquid biopsy technology.



Described as "game changing", and receiving the, "Breakthrough Innovation Award", at the World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA liquid biopsy technology earned the 2018 "Big Innovation Award", in recognition of CDA's reinvention of early cancer screening and detection.

By analyzing simple, standard, blood tests, and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA liquid biopsy technology identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from 80,000+ cases, and independently-corroborated by world-renowned hospitals and cancer research leaders, demonstrate Anpac Bio's CDA diagnostics consistently detects 26+ cancers -- with a sensitivity and specificity rate range of 75%-90%. Anpac Bio is the only company fully-commercialized and generating revenue providing liquid biopsy screening services. Over 200 CDA patent applications (70+ issued to date) have been filed worldwide.

Anpac Bio joins other prestigious, "The Big Innovation Award" winners, including: Abbott, Bechtel, Deutsche Telekom, Dow Chemicals, Harman, Hughes, Neeve Research, PepsiCo, Symphony Clinical Research, and Procter & Gamble. Presented by the Business Intelligence Group, organizations worldwide submitted their recent innovations for BIG Innovation Award consideration. Nominations were then judged by a select group of business leaders and industry executives considered international experts in each category.

"This year's winners show the diversity of innovation and its impact on the economy, our cultures and the world as a whole," said Maria Jimenez, chief operating officer of the Business Intelligence Group. "We are thrilled to be honoring Anpac Bio as they are leading by example and making real progress on improving the daily lives of so many."

For more information: www.AnpacBio.com.

 

Anpac Bio-Medical Science Company was named 2018 "BIG Innovation Award" Winner, in recognition of its global, "game-changing" research and services - particularly related to its breakthrough, “Cancer Differentiation Analysis” (CDA) liquid biopsy technology. The only company worldwide, fully-commercialized and earning revenue providing liquid biopsy screening, Anpac Bio's proprietary (200+ patents filed to date) CDA identifies 26+ different, early-stage cancers from a single, low-cost blood test.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/anpac-bio-wins-2018-international-big-innovation-award-300634254.html

SOURCE Anpac Bio

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Science,Medical Technology,Computer Science,Cancer,Business,Science,Other,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Regenerative Medicine Market Analysis Study Found Huge Boom By Rising Prevalence Of Chronic Diseases And Genetic Disorders Till 2025: Grand View Research,Inc.
  • Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer Screening & Other Applications
  • Global Sleep Apnea Diagnostic and Therapeutic Devices Strategic Business Report 2018
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground

    Cancer
  • Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
  • Altogen Labs xenograft services for drug development studies of anti-cancer therapeutics
  • HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
  • Dr. Haydee Gonzalez Hidalgo joins The Oncology Institute of Hope and Innovation
  • eClinical Solutions Market Size Is Projected To Reach $13 Billion By 2024
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines